“
TL;DR
It found no significant association between CYP2B6 genotype and therapeutic response, but specific genetic variants were linked to differences in liver and blood-related toxicities.
Scientific Reports · 10 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It found no significant association between CYP2B6 genotype and therapeutic response, but specific genetic variants were linked to differences in liver and blood-related toxicities.
The study retrospectively evaluated the association between CYP2B6 and CYP2C19 genetic variability and cyclophosphamide therapy outcomes in 50 pediatric neuroblastoma patients. Genotypes were used to assign metabolizer phenotypes, and outcomes included therapeutic response (24 responders, 26 non-responders) and organ-specific toxicities. However, poor/intermediate CYP2B6 metabolizers, defined by carrying at least one CYP2B6*6 allele, showed a significantly lower incidence of liver injury and hematologic toxicity compared to normal/rapid metabolizers. The findings suggest that CYP2B6 genotyping may help predict cyclophosphamide-induced hepatotoxicity and hematologic toxicity in pediatric neuroblastoma patients.